Tag: Antidepressant

  • New therapies may help people with dementia who suffer from depression

    New therapies may help people with dementia who suffer from depression

    About one in three people with dementia also suffer from depression. The New York Times reports on new therapies to treat older adults with dementia who suffer from depression. They address loneliness, hopelessness and anxiety in everyday life through different forms of cognitive behavioral therapy.

    In one case the psychologist worked with a 74-year old woman with mild dementia to identify her best qualities. The psychologist wrote them down and handed the paper to the patient to keep. The patient would have that paper to review when she was feeling down.

    PATH, developed at Weill-Cornell Medical Center, uses written information and film tools to treat anxiety and depression in people who struggle to remember. The goal is to help them solve challenges that present themselves on a regular basis. If possible, PATH engages a caregiver, often the patient’s spouse or family member, to help benefit from the tools. Early studies show that the therapy reduces depressive symptoms. 

    The Peaceful Mind program, developed at Baylor College of Medicine uses a simple form of cognitive behavorial therapy. It engages patients in activities that give them joy. One study shows that this person-centered approach appeared to help reduce anxiety after three months. And patients said that they had a better quality of life. But, after six months, the benefits were less clear.

    Yet another program, developed at University College London, provides patients with a stack of cards to remind them of different strategies for dealing with stress and anxiety.

    Much as dementia can lead to depression, people who suffer from depression have a higher likelihood of developing dementia. It is not clear why, but some believe that people with depression also often have high levels of the stress hormone cortisol, which can be harmful to the brain’s hippocampus. The hippocampus stores long-term memories.

    People with dementia often lack motivation and are scared. They tend to know that they are losing their ability to remember. Depression and anxiety can aggravate their dementia. Psychotherapy can be safer than prescription drugs patients with dementia and depression.

    Some research suggests that older adults with dementia are less likely to be helped by antidepressant drugs. These drugs often have dangerous side effects. For example, Prozac and other SSRIs prescribed for depression, as well as benzodiazepines, such as Klonopin and Xanax, are linked to falls in older adults. Haloperidol, risperidone and other antipsychotics and psychotropics, prescribed for anxiety, can increase the likelihood of death for patients with dementia.

    Here’s more from Just Care:

  • Don’t overlook marijuana-prescription drug interactions

    Don’t overlook marijuana-prescription drug interactions

    Middle-aged and older adults are increasingly using marijuana. As these groups tend to take more medications, marijuana-drug interactions are overlooked.

    When I think of a typical marijuana user, I admit I tend to stereotype. I see a young person, at home or with friends, smoking a large joint and having a good time. I don’t picture a grandma toking. Yet new research indicates that older people, in fact, are using cannabis more and more.

    new study found that the number of middle-aged and older adults using marijuana is on the rise. The analysis, based on the National Survey on Drug Use and Health, found that about 9% of adults between 50 and 65 had used cannabis in the last year, and about 3% of those 65 and older had. In 2013, those figures were, respectively, 7% and 1.4%.

    Laws allowing for marijuana use – either recreationally or for medical purposes – are on the rise and can explain the increase. There is some medical evidence that marijuana can be used for a variety of medical conditions, such as pain, nausea from chemotherapy, multiple sclerosis, epilepsy and seizures, and this may also help to explain the increase in the older population.

    Why Worry?

    So what’s the big deal, you might ask? Since older people tend to take multiple medications, there is a risk of marijuana potentially interacting with those drugs and undermining their effectiveness. Yet because marijuana research is limited in the US, thanks to strict restrictions from the government, it’s hard to know exactly what those impacts are.

    If older individuals – or any people, for that matter – are using marijuana for medical purposes, hopefully their doctors are aware of the medications being taken. However, if you are using marijuana and your doctors don’t know, you should tell them as soon as possible. They may be aware of potential marijuana-drug interactions.

    Despite the lack of research on marijuana-drug interactions, there are certain classes of drugs that don’t mix well with cannabis. Because marijuana is very calming on the body, taking drugs that have sedating effects is a big no-no. For example, taking benzodiazepines such as Valium (diazepam) and Xanax (alprazolam), which are used for anxiety and insomnia, or muscle relaxants can lead to central nervous system depression. The same goes with using cannabis and alcohol.

    Cannabidiol (CBD), one of the chemicals found in marijuana, is a big culprit for problems. Why? It can inhibit an enzyme in the liver that is used to break down medicines. When this happens, the medication ends up staying in the body longer, which can enhance the effects of drugs. CBD can even slow the breakdown of statin medications, used to lower cholesterol. That can increase the chances of side effects associated with statins, such as muscle pain.

    There is also evidence that marijuana can impact the effectiveness of antidepressants. This is because marijuana may speed up metabolism of the antidepressant in the body. As a result, a person may need higher doses in order to get the same effect from the antidepressant.

    More research is needed not only on the benefits and risks of marijuana as a medical treatment, but on cannabis-drug interactions. The trend in older people using marijuana makes the research all the more urgent. It’s time for the federal government to loosen restriction of cannabis research.

    This article was originally published in medshadow.org

    Here’s more from Just Care:

  • Concerns about your antidepressant? Talk to your doctor!

    Concerns about your antidepressant? Talk to your doctor!

    On April 8, 2018, the New York Times published a front-page article titled, “The Murky Perils of Quitting Antidepressants After Years of Use.” The day before, the online version, “Many People Taking Antidepressants Discover They Cannot Quit,” was the most-shared article.

    In this analysis, Benedict Carey and Robert Gebeloff describe a growing trend over the past few decades in which millions of people have been taking prescription antidepressant medications long-term. For instance, they cite data showing that over fifteen million Americans have taken antidepressants for five years or more. They go on to attribute this phenomenon mostly to antidepressants causing “dependence and withdrawal,” rather than people needing long-term antidepressants to manage psychiatric illness or choosing to remain on them because of their benefits.

    While Carey and Gebeloff do cite a few studies looking at rates of withdrawal after stopping long-term antidepressant use, they only mention one survey from New Zealand that shows that withdrawal is even a common complaint among individuals taking antidepressants. Most of their argument is based on individual stories (i.e., anecdotal evidence) combined with critiques of how antidepressants have been studied. While the individual stories are compelling and the critiques of research may be valid, this approach makes their case linking long-term antidepressant use to supposed widespread withdrawal circumstantial at best.

    Fortunately, several psychiatric care providers and even patients quickly responded to counter this somewhat misleading article. To be fair, the authors do point out that antidepressants have greatly helped millions of people, and they quote psychiatrists who are expert in treating depression, such as Dr. Peter Kramer. However, overall, the piece uses logically and scientifically shaky arguments to trigger suspicion and fear of antidepressants among the general public and mental health patients alike. Given that depression and other mental illnesses that antidepressants treat (e.g., anxiety disorders) are very common, highly impairing, sometimes dangerous, and exceedingly under-treated, this type of journalism is risky.

    The fact is, antidepressant medications are effective, especially for moderate-to-severe depression, and while all medications have side effects, newer antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are far more tolerable than older versions. In addition, the past few decades have seen a growing consensus that depression (and many other mental illnesses) is a chronic condition requiring long-term treatment, like diabetes and hypertension. (No one would say that millions of people are on long-term blood pressure medications for hypertension because of fear of withdrawal.)

    Therefore, many psychiatrists recommend (and many patients readily choose) long-term antidepressant treatment to avoid relapse once a person has had more than one depressive episode. “Withdrawal” from antidepressants (actually called discontinuation syndrome) is in fact a well-known and not-rare phenomenon. However, it is usually very mild and can be managed with a slow taper in the medication’s dose. For the relatively rare, more severe cases, a good psychiatrist can almost always reduce or eliminate it with various interventions such as adding low-dose fluoxetine (Prozac) for a while (due to its long half-life) and/or using other prescription drugs in a time-limited manner to treat discontinuation symptoms.

    Just like in any medical specialty, not all psychiatric care providers are attentive, responsive, or skilled enough to avoid or successfully manage discontinuation syndrome, but that’s a different problem that can’t be solved by avoiding antidepressant treatment to begin with. So, rather than an inability to stop them due to “withdrawal,” doesn’t it seem much more likely that growing numbers of people are on antidepressant treatment long-term either because they need the medication to prevent symptoms from returning and/or choose to remain on the medication because of low side effect burden and protection against relapse?

    The article does make some valid and important points. The research on antidepressants mostly involves relatively short-term studies, so there is a great need to examine the longer-term efficacy and adverse effects of these prescription drugs. And the discontinuation syndrome has received far too little research attention.

    These deficits in the science are indeed likely due to pharmaceutical companies having little incentive to investigate prescription drugs that have gone generic or to emphasize problems with the products they produce and market. However, it is unfortunate that these valid critiques were packaged into a misleading and highly public message, which has the potential to discourage people from seeking treatment for mental illness and encourage patients to stop their medications.

    Advice from this psychiatrist: Discuss your goals for treatment and any problems with medications with your healthcare provider before changing or stopping them on your own. No one – not even your doctor! – can force you to stay on a medication that you no longer want to take, but only an experienced professional can help you to change medications in a safe and healthy way.

    Here’s more from Just Care:

  • Common OTC drugs linked to cognitive impairment

    Common OTC drugs linked to cognitive impairment

    Common over-the-counter (OTC) medicines used to treat colds and allergies, as well as sleep aids, are linked to cognitive impairment in older adults, including an increased risk of dementia.

    It’s more than likely that the medicines, which are known as anticholinergic drugs, are in your medicine cabinet. Some common brand names are Benadryl (diphenhydramine), Dramamine (dimenhydrinate), and Dimetapp (dextromethorphan), a commonly used cough suppressant found in cold remedies.

    Older types of antidepressants (tricyclic) and bupropion, better known as Wellbutrin as an antidepressant and Zyban as a smoking aid, are also anticholinergic agents. Other medications with known anticholinergic effects are sold OTC as sleep aids, and with a prescription to treat chronic conditions, including cardiovascular disease, chronic obstructive pulmonary disease (COPD) and hypertension.

    Using brain scans, researchers at the Indiana University School of Medicine found that people who took anticholinergic drugs had a lower metabolism and smaller brain sizes. The drugs work by blocking acetylcholine, a chemical known as a neurotransmitter that operates in the nervous system.

    “Given all of the research evidence, physicians might want to reconsider anticholinergic medications if available when working with their older patients,” first author Shannon Risacher, PhD, assistant professor of radiology and imaging science, said in a statement. The study was published in JAMA Neurology in 2016.

    The research involved 451 people, 60 of whom were taking at least one medication considered to have medium to high anticholinergic activity. Those taking the drugs didn’t do as well as older adults on memory based on cognitive tests, as well as other tests used to measure activities including verbal reasoning, planning and problem solving, which are known as executive functions.

    This study is not the first to find a link between anticholinergic drugs and cognitive issues in older adults. In 2003, another Indiana University team found that meds with a significant anticholinergic effect can cause cognitive issues in as little as 60 days of continuous use. And drugs with a weaker effect could cause impairment within 90 days.

    This post was first published in www.medshadow.org.

    Here’s more from Just Care:

  • Will your health plan cover the drugs you need?

    Will your health plan cover the drugs you need?

    Health plans often make it hard for people to know which drugs they cover before they sign up for the plan and even harder to find out what out-of-pocket costs will be for a particular drug. Yet, different drugs in a particular class may work better or worse for a particular person.

    If you have Medicare, you should be able to find out online quite quickly whether a Part D prescription drug plan covers the anti-depressant you need.  But, a new Urban Institute study suggests that people in the health insurance exchanges may have difficulty knowing whether a health plan meets their drug needs.  

    The study looked at health plan coverage of anti-depressants in five state health exchanges and found significant differences among them in drugs covered and willingness to disclose which drugs were covered. Antidepressants are the third most commonly used prescription drug. More than one in 10 Americans over 12 take them.

    Out of 35 health plans studied, nine excluded more than five antidepressants from coverage and some excluded up to 15.  

    Allowing the plans to list drugs they cover in whatever way they choose can make it extremely hard for people to determine whether a drug is covered. And, even when people can see a drug they take is covered, it can be hard for them to know what their out-of-pocket costs will be in advance of enrolling in a plan. People in plans that charge co-insurance for drugs are generally left in the dark.

    The study recommends that the state exchanges offer direct links to easily searchable lists for each plan, make it easier for an individual to appeal the non-coverage of a drug, and monitor the process to ensure its fairness; it also recommends that out-of-pocket costs be predictable.